Ampyra Seizure Warnings Strengthened Followed Continued Reports
This article was originally published in The Pink Sheet Daily
Executive Summary
The seizure risk for Acorda’s multiple sclerosis drug was already known, but an FDA MedWatch Alert based on post-market adverse event reports says, “the majority of seizures happened within days to weeks after starting the recommended dose and occurred in patients having no history of seizures.”
You may also be interested in...
Ampyra Trial Failure Is Not All Bad News For Acorda
Lower dose of Acorda’s MS drug Ampyra fails to meet primary endpoint in new study, reassuring investors on the IP front. But the higher, approved dose also missed the mark, which raises questions about a negative commercial impact.
Ampyra Trial Failure Is Not All Bad News For Acorda
Lower dose of Acorda’s MS drug Ampyra fails to meet primary endpoint in new study, reassuring investors on the IP front. But the higher, approved dose also missed the mark, which raises questions about a negative commercial impact.
Ampyra Trial Failure Is Not All Bad News For Acorda
Lower dose of Acorda’s MS drug Ampyra fails to meet primary endpoint in new study, reassuring investors on the IP front. But the higher, approved dose also missed the mark, which raises questions about a negative commercial impact.